Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. filed a Form 8-K to report that it issued a press release on September 29, 2025 announcing changes to the executive management teams of ASP Isotopes Inc. and its subsidiary, Quantum Leap Energy LLC, effective October 1, 2025. The press release describing these leadership changes is included as Exhibit 99.1 and incorporated by reference, except for its third through seventh paragraphs.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has become the controlling shareholder of Skyline Builders Group Holding Limited (SKBL), a Cayman Islands company listed on Nasdaq under “SKBL”. QLE plans to use SKBL to pursue acquisitions of critical materials supply-chain assets that it believes are important for U.S. security and QLE’s long-term growth.
On August 27, 2025, QLE bought all 1,995,000 Class B Ordinary Shares of SKBL from the prior controller for $1,000,000. Each Class B share carries 20 votes, compared with one vote for each Class A share. On August 29, 2025, SKBL completed a Private Placement, issuing 1,359,314 Class A shares plus multiple series of warrants and receiving $17,775,000 in gross proceeds. QLE invested $1,500,000 for Class A shares and warrants, while about $7,000,000 of the proceeds were used to retire 18,500,000 Class A shares held by the former controlling shareholder.
After these steps, QLE holds 79.14% of the aggregate voting power of SKBL and therefore controls the company. ASP Isotopes’ Chairman and CEO, Paul Mann, separately invested $2,500,000 personally in SKBL shares and warrants, subject to a 4.99% beneficial ownership cap on warrant exercises.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has become the controlling shareholder of Skyline Builders Group Holding Limited (SKBL), a Cayman Islands company listed on Nasdaq under “SKBL”. QLE plans to use SKBL to pursue acquisitions of critical materials supply-chain assets that it believes are important for U.S. security and QLE’s long-term growth.
On August 27, 2025, QLE bought all 1,995,000 Class B Ordinary Shares of SKBL from the prior controller for $1,000,000. Each Class B share carries 20 votes, compared with one vote for each Class A share. On August 29, 2025, SKBL completed a Private Placement, issuing 1,359,314 Class A shares plus multiple series of warrants and receiving $17,775,000 in gross proceeds. QLE invested $1,500,000 for Class A shares and warrants, while about $7,000,000 of the proceeds were used to retire 18,500,000 Class A shares held by the former controlling shareholder.
After these steps, QLE holds 79.14% of the aggregate voting power of SKBL and therefore controls the company. ASP Isotopes’ Chairman and CEO, Paul Mann, separately invested $2,500,000 personally in SKBL shares and warrants, subject to a 4.99% beneficial ownership cap on warrant exercises.
ASP Isotopes Inc. has extended the deadline to complete its planned acquisition of Renergen Limited, giving more time to meet closing conditions. Under the proposed South African scheme of arrangement, Renergen shareholders would receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.
The longstop date has been moved from September 30, 2025 to November 28, 2025 to obtain remaining regulatory approval and third-party consents. Implementation of the scheme still depends on approval from the Financial Surveillance Department of the South African Reserve Bank, and both companies continue to work toward timely approval.
Robert Ainscow, Chief Operating Officer of ASP Isotopes Inc. (ASPI), reported multiple transactions on September 8-9, 2025. On 09/08/2025 he executed "sell to cover" sales under a Rule 10b5-1 plan totaling 8,438 shares at a weighted average price of $8.5263 to cover tax withholding from vested restricted stock. On 09/09/2025 he was granted or exercised employee stock options: option grants/exercises include 150,000 options at $0.25, 12,000 options at $2, and 135,000 options at $2, increasing beneficial ownership by option awards to positions listed. Net-share settlements of option exercises resulted in withholding of 4,396, 2,813, and 31,652 shares. After the reported transactions the filing person beneficially owned 1,669,693 shares.
Insider transactions by Paul Elliot Mann, CEO, director and 10% owner of ASP Isotopes Inc. (ASPI). The Form 4 reports multiple transactions on September 8-9, 2025. The filing shows sales totaling 447,263 shares disposed through Rule 10b5-1 "sell to cover" and net-share settlements at weighted-average prices reported around $8.14–$8.58. The reporting person also acquired or was issued stock/derivative awards: 216,000 and 1,000,000 employee stock options (exercise price $2) reported as acquired on 09/09/2025. Following these transactions, the reporting person beneficially owned 8,084,191 shares (direct).
The filing discloses that some dispositions were effected under a 10b5-1 trading plan adopted June 9, 2025 to cover tax withholding for vesting restricted stock and that other share withholdings satisfied option exercise obligations. No additional financial results or forward-looking statements are included.
Form 144 filing for ASP Isotopes Inc. (ASPI) reports a proposed sale of 8,438 shares of common stock through Independent Trading Group (ITG) on NASDAQ with an aggregate market value of $69,191.60. The filer acquired 300,000 shares on 09/06/2024 as a restricted stock award from the issuer and indicates the securities were granted as equity compensation. The filing shows 91,913,109 shares outstanding for the issuer and lists the approximate sale date as 09/08/2025. No securities were reported sold by the filer in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 Notice: The filing discloses a proposed sale of 8,438 shares of common stock of ASP Isotopes Inc. (ASPI) with an aggregate market value of $69,191.60. The securities are to be sold through Independent Trading Group (ITG) Inc., and the sale is identified for 09/08/2025 on the NASDAQ. The filer acquired 300,000 shares on 09/06/2024 as a restricted stock award from the issuer and the acquisition was paid as equity compensation on the same date. The form states there were no sales by the filer in the prior three months and includes the standard signature representation regarding material nonpublic information.
ASP Isotopes Inc. reported that its Board of Directors increased its size to seven members and elected Ralph L. Hunter as a Class II director, effective September 8, 2025. His term will run until the Company’s 2027 annual meeting of stockholders or until earlier resignation or removal, and he was also named to the Board of Managers of Quantum Leap Energy LLC, a wholly owned subsidiary.
Hunter, age 60, has over 35 years of nuclear power generation experience, including leadership roles at RC Nuclear Consultants, Orion Nuclear Energy, and Constellation-related nuclear development entities, as well as service on the U.S. Civil Nuclear Trade Advisory Committee. In connection with his election, he received an award of 10,470 shares of restricted stock under the 2022 Equity Incentive Plan, vesting in full on the one-year anniversary of the grant date, and will be compensated under the Company’s non-employee director compensation policy.
Moore Duncan, a director of ASP Isotopes Inc. (ASPI), reported the sale of 75,000 shares on 08/29/2025 at a weighted average price of $9.2831. After the sale he beneficially owned 994,553 shares. The filing states the sale included shares sold to satisfy income tax liabilities arising from the vesting of a previously granted restricted stock award for 200,000 shares. The weighted-average price represents multiple trades executed between $8.95 and $10.20. The Form 4 was signed by an attorney-in-fact on 09/03/2025. This disclosure records an insider disposition tied to tax withholding for a stock award.
ASP Isotopes Inc. filed a current report to disclose that it issued a letter to shareholders dated September 2, 2025. The company is furnishing this shareholder letter as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is intended to provide broadly available information to the market. The filing specifies that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other SEC documents if specifically referenced.